PT - JOURNAL ARTICLE AU - Sohan Singh Hayreh TI - Controversies on neuroprotection therapy in non-arteritic anterior ischaemic optic neuropathy AID - 10.1136/bjophthalmol-2019-314656 DP - 2020 Feb 01 TA - British Journal of Ophthalmology PG - 153--156 VI - 104 IP - 2 4099 - http://bjo.bmj.com/content/104/2/153.short 4100 - http://bjo.bmj.com/content/104/2/153.full SO - Br J Ophthalmol2020 Feb 01; 104 AB - Objective There has long been a great interest in neuroprotection therapy for ischaemic stroke and various types of optic neuropathies. In view of that, I reviewed the literature on the role of neuroprotection for non-arteritic anterior ischaemic optic neuropathy (NA-AION).Methods The review is based on a PubMed search of literature about the use of neuroprotectors in stroke and optic neuropathies and about current clinical trials of RPh201 and QPI-1007 in NA-AION.Results Several neuroprotection agents for ischaemic stroke and various types of optic neuropathies have been evaluated extensively in experimental studies in animals and benefits claimed. However, translation of therapeutic strategies for neuroprotection from experimental research to humans has invariably been fraught with failure. Two currently ongoing studies dealing with neuroprotection by RPh201 and QPI-1007 in NA-AION may have limitations in their rationale and study designs.Conclusions Unfortunately, in spite of all the experimental and clinical research on neuroprotection agents in NA-AION so far, we have no scientifically proven evidence of neuroprotection agents showing any benefit in the human clinical studies so far.